Tekla Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Tekla Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-149,835	Closed	-$1.34M	–	220
2020 Q2	$1.34M	Hold	149,835	–	–	0.05%	183
2020 Q1	$954K	Hold	149,835	–	–	0.04%	179
2019 Q4	$1.25M	Buy	+149,835	New	+$1.38M	0.05%	176
2019 Q3	–	Sell	-120,768	Closed	-$1.3M	–	197
2019 Q2	$1.3M	Sell	120,768 -120,770	-50%	-$1.28M	0.05%	156
2019 Q1	$2.3M	Hold	241,538	–	–	0.09%	125
2018 Q4	$2.77M	Buy	241,538 +69,649	+41%	+$865K	0.12%	113
2018 Q3	$2.91M	Buy	171,889 +51,377	+43%	+$781K	0.11%	126
2018 Q2	$1.71M	Buy	+120,512	New	+$2M	0.06%	141
2015 Q3	–	Sell	-75,000	Closed	-$832K	–	168
2015 Q2	$832K	Sell	75,000 -604,100	-89%	-$7.79M	0.03%	108
2015 Q1	$10.6M	Hold	679,100	–	–	0.42%	58
2014 Q4	$10.3M	Sell	679,100 -71,000	-9%	-$862K	0.48%	50
2014 Q3	$8.09M	Buy	750,100 +629,700	+523%	+$8.22M	0.38%	57
2014 Q2	$1.84M	Buy	120,400 +73,000	+154%	+$1.05M	0.17%	59
2014 Q1	$857K	Buy	+47,400	New	+$914K	0.09%	60

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tekla Capital Management's SGMO Position: Q3 2020 in Review

Tekla Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2020, closing a stake of 149,835 shares — an estimated $1.34M sold.

Tekla Capital Management first reported a position in SGMO in Q1 2014 and held it in 14 quarters. The position peaked at $10.6M in Q1 2015. 210 funds tracked by Wall St. Rank hold SGMO as of Q3 2020.

Tekla Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2020 after selling out during the quarter.
Tekla Capital Management sold 149,835 SANGAMO THERAPEUTICS INC shares in Q3 2020, an estimated $1.34M.
Tekla Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q1 2014 and held it in 14 quarters.
Tekla Capital Management's SANGAMO THERAPEUTICS INC position peaked at $10.6M in Q1 2015.
210 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2020.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.